Kevin D Boyd

List of Publications by Year
in descending order

52 papers	1,707 citations	430442 18 h-index	288905 40 g-index
52 all docs	52 docs citations	52 times ranked	2736 citing authors

#	Article	IF	Citations
1	Characterising spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: Towards macro-phenotype driven patient management. Magnetic Resonance Imaging, 2021, 75, 60-64.	1.0	9
2	Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 667-675.	0.2	12
3	Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. Lancet Haematology,the, 2021, 8, e389-e392.	2.2	121
4	Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. Radiology Imaging Cancer, 2021, 3, e210048.	0.7	22
5	Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (â‰¥2nd) Tj ETQq1 1 0.784314 rgBT /O 1396-1404.	0.6	5
6	Interobserver agreement of whole-body magnetic resonance imaging is superior to whole-body computed tomography for assessing disease burden in patients with multiple myeloma. European Radiology, 2020, 30, 320-327.	2.3	18
7	An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma. International Journal of Laboratory Hematology, 2020, 42, e65-e67.	0.7	2
8	Inter-observer agreement of baseline whole body MRI in multiple myeloma. Cancer Imaging, 2020, 20, 48.	1.2	6
9	Improving realâ€world myeloma patient access to whole body MRI through â€œopenâ€•accessâ€•knowledge sharing: The UK experience. EJHaem, 2020, 1, 361-363.	0.4	2
10	A realâ€world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multipleâ€•myeloma patients. British Journal of Haematology, 2020, 191, 927-930.	1.2	5
11	DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 53-54.	0.6	13
12	Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. Haematologica, 2020, Online ahead of print, 0-0.	1.7	16
13	Multiple myeloma: an overview of management. Palliative Care and Social Practice, 2019, 13, 117822421986823.	0.6	41
14	Detection of avascular necrosis on routine diffusion-weighted whole body MRI in patients with multiple myeloma. British Journal of Radiology, 2019, 92, 20180822.	1.0	6
15	Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone. Blood, 2018, 132, 4482-4482.	0.6	6
16	Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial. Blood, 2018, 132, 3274-3274.	0.6	1
17	Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma. Blood, 2018, 132, 3237-3237.	0.6	0
18	Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial. Blood, 2018, 132, 3280-3280.	0.6	2

#	Article	IF	Citations
19	The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a â€œreal-worldâ€•study: the Royal Marsden Hospital experience. Leukemia and Lymphoma, 2017, 58, 494-497.	0.6	14
20	Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report. BMC Cancer, 2017, 17, 718.	1.1	16
21	Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.. Journal of Clinical Oncology, 2017, 35, 2506-2506.	0.8	22
22	Durvalumab (DURVA) plus daratumumab (DARA) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2017, 35, TPS8054-TPS8054.	0.8	2
23	Absolute Lymphocyte Count at Day 29 of Treatment Is a Powerful Predictor of Outcome in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 222-226.	0.2	4
24	Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); A Report of Second Primary Malignancy (SPM) Rates and the Importance of Review of Reported Cases. Blood, 2015, 126, 1847-1847.	0.6	1
25	Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma <scp>IX</scp> Study results. British Journal of Haematology, 2014, 166, 109-117.	1.2	28
26	Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after highâ€dose therapy. British Journal of Haematology, 2013, 161, 291-294.	1.2	4
27	Understanding the molecular biology of myeloma and its therapeutic implications. Expert Review of Hematology, 2012, 5, 603-617.	1.0	14
28	Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. British Journal of Haematology, 2012, 156, 552-555.	1.2	33
29	Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results.. Journal of Clinical Oncology, 2012, 30, 8015-8015.	0.8	1
30	Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood, 2011, 117, 553-562.	0.6	217
31	The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomideâ€based therapy. Genes Chromosomes and Cancer, 2011, 50, 765-774.	1.5	59
32	Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1703-1707.	1.1	39
33	Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival. Clinical Cancer Research, 2011, 17, 7776-7784.	3.2	147
34	Novel Drugs in Myeloma: Harnessing Tumour Biology to Treat Myeloma. Recent Results in Cancer Research, 2011, 183, 151-187.	1.8	7
35	The Interaction of Response and FISH-Based Risk Stratification to Better Define Clinical Outcome in Myeloma. Blood, 2011, 118, 1823-1823.	0.6	0
36	XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood, 2010, 116, 250-253.	0.6	107

#	Article	IF	Citations
37	A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood, 2010, 116, e56-e65.	0.6	315
38	The potential role of epigenetic therapy in multiple myeloma. British Journal of Haematology, 2010, 148, 702-713.	1.2	60
39	The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. British Journal of Haematology, 2010, 150, 326-333.	1.2	57
40	Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome. Clinical Cancer Research, 2010, 16, 1856-1864.	3.2	124
41	High expression levels of the mammalian target of rapamycin inhibitorDEPTORare predictive of response to thalidomide in myeloma. Leukemia and Lymphoma, 2010, 51, 2126-2129.	0.6	26
42	Hypermethylation Is A Key Feature of the Transition of Multiple Myeloma to Plasma Cell Leukemia. Blood, 2010, 116, 535-535.	0.6	1
43	Defining Myeloma Patients at High Risk of Developing Bone Disease While on Bisphosphonate Treatment. Blood, 2010, 116, 782-782.	0.6	3
44	The Introduction of Novel Agents Improves Outcomes of Young Patients with Myeloma (MM) Treated with Autologous Stem Cell Transplant (ASCT). Blood, 2010, 116, 1348-1348.	0.6	0
45	Defining High Risk Myeloma Using Co-Segregating FISH Variables; Results of MRC Myeloma IX. Blood, 2010, 116, 1907-1907.	0.6	1
46	Liposomal cytarabine in cerebrospinal fluid. British Journal of Haematology, 2009, 145, 679-679.	1.2	3
47	The impact of extramedullary disease at presentation on the outcome of myeloma. Leukemia and Lymphoma, 2009, 50, 230-235.	0.6	97
48	UTX, a Histone Demethylase, Is Inactivated through Homozygous Deletion, Mutation, and DNA Methylation in Multiple Myeloma.. Blood, 2009, 114, 1798-1798.	0.6	0
49	Alemtuzumab in the treatment of chronic lymphocytic lymphoma. Expert Review of Anticancer Therapy, 2008, 8, 525-533.	1.1	18
50	Autologous Transplantation Is the Optimum Approach to the Management of Myeloma Patients with Extramedullary Disease at Presentation. Blood, 2008, 112, 3313-3313.	0.6	0
51	B- Cell Chronic Lymphocytic Leukaemia Complicated by Aggressive T-Cell Lymphoma: Clinical and Molecular Analysis of a Rare Variant of Richterâ€™s Syndrome.. Blood, 2005, 106, 4999-4999.	0.6	0
52	The genetic and epigenetic mechanisms underlying the behavior of myeloma. , 0, , 48-63.		0